Close Menu

NEW YORK – Swedish genetic test developer Devyser announced Wednesday it has received CE marking for its next-generation sequencing-based hereditary breast and ovarian cancer assay.

The targeted sequencing test analyzes 12 genes and uses a proprietary amplification-based library preparation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.